Free Trial
NASDAQ:AVTX

Avalo Therapeutics Q3 2023 Earnings Report

Avalo Therapeutics logo
$8.82 +0.47 (+5.57%)
As of 11:53 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Avalo Therapeutics EPS Results

Actual EPS
-$26.40
Consensus EPS
-$264.00
Beat/Miss
Beat by +$237.60
One Year Ago EPS
N/A

Avalo Therapeutics Revenue Results

Actual Revenue
$0.24 million
Expected Revenue
$1.00 million
Beat/Miss
Missed by -$760.00 thousand
YoY Revenue Growth
N/A

Avalo Therapeutics Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Wednesday, November 8, 2023
Conference Call Time
6:00PM ET

Avalo Therapeutics Earnings Headlines

The Coin That Could Define Trump’s Crypto Presidency
When Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top advisor on crypto and AI. That alone signaled a shift. But insiders close to D.C. aren’t just talking crypto policy—they’re quietly buying something most retail investors have missed. While the crowd chases Bitcoin to $150,000, Weiss Ratings expert Juan Villaverde believes a different coin—already backed by giants like Google, Visa, and PayPal—could soon become crypto’s “Third Giant.”
See More Avalo Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Avalo Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Avalo Therapeutics and other key companies, straight to your email.

About Avalo Therapeutics

Avalo Therapeutics (NASDAQ:AVTX), a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

View Avalo Therapeutics Profile

More Earnings Resources from MarketBeat